Clinical Trials

12 enrolled

EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

NCT07020065 2026-04-15

Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%

156 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07527325 2026-04-14

Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma

35 enrolled

Melanoma

NCT05553834 2026-04-13

PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung

60 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06865339 2026-04-13

TRIPL

76 enrolled

NSCLC

NCT06790602 2026-04-09

SWITCH

43 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT07511036 2026-04-06

PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable Melanoma

20 enrolled

Melanoma

NCT07001618 2026-04-03

IMMUNOLIFE2

162 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07188896 2026-04-03

A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)

120 enrolled

Carcinoma, Renal Cell

NCT05929664 2026-03-24

Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery

70 enrolled

Carcinoma, Basal Cell

NCT06651593 2026-03-24

Phase II Biomarker Study of SAR444881 in Combination With Cemiplimab in Solid Tumors

40 enrolled

Other solid neoplasm

Solid Tumors

NCT06943664 2026-03-24

Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer

27 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07281768 2026-03-20

Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer

66 enrolled

Adenocarcinoma, Carcinoma, Rectal Neoplasms, Colorectal Neoplasms

NCT06205836 2026-03-17

Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer

44 enrolled

Adenocarcinoma, Carcinoma, Colorectal Neoplasms

NCT01042379 2026-03-13

I-SPY

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT05401786 2026-03-12

RAD-IO

54 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06981325 2026-03-11

CEMI-first

34 enrolled

Carcinoma, Basal Cell, Skin Neoplasms

NCT06385262 2026-03-06

TOP 2301: Neoadjuvant Chemo for NSCLC

Phase 2 Suspended

126 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06699602 2026-03-04

A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma

10 enrolled

Carcinoma, Renal Cell

NCT07179315 2026-03-04

A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After Treatment

68 enrolled

Head and Neck Neoplasms

NCT07450183 2026-03-04

Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1

33 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04988074 2026-03-03

MINIMA

32 enrolled

HPV-Related Squamous Cell Carcinoma

NCT07223541 2026-03-02

LAG-BOOST

72 enrolled

Carcinoma, Renal Cell

NCT03565783 2026-02-25

Cemiplimab in Treating Patients With Recurrent and Resectable Stage II-IV Head and Neck Cutaneous Squamous Cell Cancer Before Surgery

44 enrolled

DermatologicHead & Neck

Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck

NCT07433673 2026-02-25

GAP Cemi

20 enrolled

Rectal Neoplasms

NCT06918132 2026-02-24

N-PLANC

60 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06855212 2026-02-20

Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC

21 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT07418931 2026-02-18

CECYDE

108 enrolled

Advanced Squamous Non-Small Cell Lung Cancer

NCT07414992 2026-02-17

A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder Cancer

44 enrolled

Urinary Bladder Neoplasms

NCT06731270 2026-02-12

Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy

20 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06656598 2026-02-11

SPORADIC

152 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07234058 2026-02-11

LAG-MAPS

Other solid neoplasmThoracic

126 enrolled

Mesothelioma, Malignant

NCT04862650 2026-02-10

Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

46 enrolled

Squamous Cell Carcinoma of Head and Neck, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT07360743 2026-02-10

META-1

275 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07224022 2026-02-04

NACho

24 enrolled

Colonic Neoplasms

NCT06860815 2026-01-28

Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer

11 enrolled

Breast

Breast Neoplasms

NCT05694871 2026-01-26

Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma

77 enrolled

Sarcoma

Liposarcoma

NCT07346196 2026-01-20

A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck

90 enrolled

Tumor-Agnostic

Carcinoma, Squamous Cell

NCT06444880 2026-01-08

Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies

40 enrolled

SMARCB1-Deficient Malignancies

NCT07274384 2025-12-10

HYPERBOLIC

74 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasms, Disease Progression

NCT06448026 2025-12-05

Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity Squamous Cell Carcinoma (OCSCC).

17 enrolled

Mouth Neoplasms

NCT06121180 2025-12-04

Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma

32 enrolled

Uveal Melanoma

NCT04315701 2025-11-20

A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer

35 enrolled

Skin Neoplasms

NCT06917573 2025-11-19

PALACE

63 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT05961709 2025-10-24

The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer

50 enrolled

Colonic Neoplasms

NCT06623656 2025-10-23

Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC

112 enrolled

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT07085572 2025-10-06

INTERVAL

31 enrolled

Endocrine

Adrenocortical Carcinoma

NCT06528769 2025-09-30

Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma

16 enrolled

Sarcoma

Leiomyosarcoma, Sarcoma

NCT04243616 2025-09-05

CemiHALT